DGAP-News: Biotest AG: Biotest with new management team for research and regulatory affairs
(firmenpresse) - DGAP-News: Biotest AG / Key word(s): Change of Personnel
Biotest AG: Biotest with new management team for research and
regulatory affairs
13.12.2012 / 09:00
---------------------------------------------------------------------
PRESS RELEASE
Biotest with new management team for research and regulatory affairs
- Dr. Jörg Schüttrumpf takes over responsibility for pre-clinical
research and development as new Head of Global Research
- Experienced physician and pharmaceutical manager Prof. Dr. Markus
Rothenburger is assuming the position as Head of Medical/ Regulatory
Affairs at the beginning of next year
Dreieich, December 13, 2012. Biotest AG is realigning the Global Research
and Medical/Regulatory Affairs divisions. Dr. Jörg Schüttrumpf (38) is new
Head of Global Research since the beginning of November 2012. The medical
doctor (MD), who has been with Biotest since July 2012, is responsible for
early research and development in the important areas immunology,
haematology and intensive care. This includes new projects using
recombinant technologies as well as new pre-clinical research and
development projects within plasma proteins.
Biotest Chairman Prof. Dr. Gregor Schulz comments: 'We are delighted to
have Dr. Schüttrumpf on board. He is the ideal candidate to head this
important area. Dr. Schüttrumpf is a specialist in the fields of
coagulation research and transfusion medicine, and was therefore our first
choice for this position.' Before joining Biotest, Dr. Schüttrumpf's career
included positions at Essen und Frankfurt am Main university hospitals as
well as at the blood donor service DRK-Blutspendedienst
Baden-Württemberg-Hessen. Dr. Schüttrumpf specialised in the field of
transfusion medicine. He also conducted research projects over several
years at the Children's Hospital of Philadelphia at the University of
Pennsylvania.
In addition, the position Head of Medical/Regulatory Affairs will also be
filled at the beginning of 2013. Prof. Dr. Markus Rothenburger (46) will be
responsible for the clinical development of new active substances and
regulatory affairs. Prof. Rothenburger worked at various hospitals for 13
years in vascular and heart surgery as well as in intensive care medicine.
He is a recognised specialist, with over 150 publications in renowned
scientific journals. In 2006 he moved to the pharmaceutical industry and
had leading positions at companies such as Novartis and Fresenius Kabi. 'We
are delighted to have recruited Prof. Dr. Rothenburger. We win an excellent
medical specialist and a pharmaceutical manager with wide-ranging industry
connections,' Prof. Dr. Schulz explains regarding this appointment: 'The
recruitment of top professionals for both of these important positions
means that we are well positioned for research and development within the
management level below the Board level.'
Disclaimer
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments.
The forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.
About Biotest
Biotest is a provider of pharmaceutical and biotherapeutic drugs. With a
value added chain that extends from pre-clinical and clinical development
to worldwide sales, Biotest has specialised primarily in the areas of
application of clinical immunology, haematology and intensive medicine. In
its Plasma Protein portfolio Biotest develops and markets immunoglobulins,
coagulation factors and albumins based on human blood plasma. These are
used for diseases of the immune and haematopoietic systems. Biotest also
researches into the development of monoclonal antibodies, including in the
indications of rheumatoid arthritis and cancer of plasma cells. Biotest has
more than 1.600 employees worldwide. The preference shares of Biotest AG
are listed in the SDAX on the Frankfurt stock exchange.
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de
Dr. Monika Buttkereit
tel.: +49 (0) 6103 801-4406,
e-mail: investor_relations(at)biotest.de
fax: +49 (0) 6103 801-347
Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover,
München, Stuttgart
End of Corporate News
---------------------------------------------------------------------
13.12.2012 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Germany
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: investor_relations(at)biotest.de
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Indices: SDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
196858 13.12.2012
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 13.12.2012 - 09:00 Uhr
Sprache: Deutsch
News-ID 212365
Anzahl Zeichen: 7037
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 267 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Biotest AG: Biotest with new management team for research and regulatory affairs"
steht unter der journalistisch-redaktionellen Verantwortung von
Biotest AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
